Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate
Eric L. Sievers(Seagen (United States)), Irwin D. Bernstein(Fred Hutch Cancer Center), Stephen J. Forman(City Of Hope National Medical Center), Ricardo Spielberger(City of Hope), Frederick R. Appelbaum(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), David Flowers(City Of Hope National Medical Center), FO Smith(City Of Hope National Medical Center), M. S. Berger(City Of Hope National Medical Center), Kathleen Shannon‐Dorcy(City Of Hope National Medical Center)
Cited by 439
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k